A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection
BIOLOGICAL: V504|BIOLOGICAL: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|BIOLOGICAL: Comparator: Placebo (unspecified)
Geometric mean titers (GMTs) to HPV types contained in the administered vaccines, 4 weeks post dose 3
Seroconversion percentages to HPV types contained in the administered vaccines, 4 weeks post dose 3
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.